3 results match your criteria: "Venereology and Pediatric Dermatology Medical University of Lublin[Affiliation]"
Extended Inflammation Parameters (EIP) as Markers of Inflammation in Systemic Sclerosis.
Int J Inflam
September 2024
Department of Biochemical Diagnostics Chair of Laboratory Diagnostics Medical University of Lublin, al. Solidarności 8, Lublin 20-081, Poland.
Background: Systemic sclerosis (SSc) is an autoimmune disease characterized by inflammation, progressive vasculopathy, and fibrosis of skin and internal organs. The aim of the study was to evaluate extended inflammatory parameters (EIP) in patients with SSc in comparison to the control group of healthy subjects.
Methods: A total of 28 patients with SSc and 29 healthy controls (HCs) were included in the study.
Risankizumab Therapy for Moderate-to-Severe Psoriasis-A Multi-Center, Long-Term, Real-Life Study from Poland.
J Clin Med
February 2023
Department of Dermatology, Venereology and Pediatric Dermatology Medical University of Lublin, 20-081 Lublin, Poland.
Article Synopsis
- A multi-center study in Poland assessed the effectiveness of risankizumab for treating moderate-to-severe plaque psoriasis in 185 patients over a long-term period.
- The severity of psoriasis was measured using the Psoriasis Area and Severity Index (PASI) at multiple timepoints (4 to 96 weeks), tracking percentages of patients achieving significant responses (PASI90 and PASI100).
- Results showed increasing PASI90 and PASI100 responses over time, with some correlations noted between treatment outcomes and factors like age, duration of psoriasis, and the presence of psoriatic arthritis.
Therapeutic hotline: Primary cutaneous CD4 + small/medium-sized pleomorphic T cell lymphoma coexisting with myelodysplastic syndrome transforming into chronic myelomonocytic leukemia successfully treated with cyclophosphamide.
Dermatol Ther
February 2011
Chair and Department of Dermatology, Venereology and Pediatric Dermatology Medical University of Lublin, Prague, Czech Republic.
Cutaneous T cell lymphomas other than mycosis fungoides, Sezary syndrome, and primary cutaneous CD30+ lymphoproliferations constitute less than 10% of all cutaneous T cell lymphomas. Primary cutaneous small/medium CD4+ T cell lymphoma is a member of this third group of cutaneous lymphomas, separated out as provisional entity in the World Health Organization classification - European Organization for Research and Treatment of Cancer (WHO-EORTC) classification. It still awaits development of more precise diagnostic criteria and optimal therapy.
View Article and Find Full Text PDF